IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1295.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 13-Apr-2016
The International Liver CongressTM 2016
High rate of cancer recurrence found in certain hepatitis C patients
Data from a new study show that patients with hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer had a 'high rate' of re-developing their illness.

Contact: ILC Press office
ilcpressoffice@ruderfinn.co.uk
44-020-743-83054
European Association for the Study of the Liver

Public Release: 13-Apr-2016
PLOS ONE
UCLA research suggests that gut bacteria could help prevent cancer
New research offers evidence that anti-inflammatory 'health beneficial' gut bacteria can slow or stop the development of some types of cancer.
National Institutes of Health

Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-794-2273
University of California - Los Angeles Health Sciences

Public Release: 13-Apr-2016
Oncogene
Cartilage protein may contribute to the development of breast cancer
Research from Lund University in Sweden shows that the protein COMP, which mainly exists in cartilage, can also be found in breast cancer tumors in patients with a poor prognosis. Studies on mice also showed that COMP contributed to the development and metastasis of the breast cancer.

Contact: Cecilia Schubert
cecilia.schubert@kommunikation.lu.se
46-073-062-3858
Lund University

Public Release: 13-Apr-2016
Nature
Repairing DNA damage in the human body
UNSW medical scientists have discovered that DNA repair is compromised at important regions of our genome, shedding new light on the human body's capacity to repair DNA damage.
Cancer Institute NSW, Cure Cancer Australia Foundation, Cancer Australia

Contact: Dan Wheelahan
d.wheelahan@unsw.edu.au
61-435-930-465
University of New South Wales

Public Release: 13-Apr-2016
Scientific Reports
New method to preserve microfluidic devices for HIV monitoring in developing countries
Inspired by pregnancy tests, researchers at FAU and their collaborators have developed a novel method to store microfluidic devices for CD4 T cell testing in extreme weather conditions for up to six months without refrigeration. These devices have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. If produced at a large scale, the device would cost less than $1 compared with the current cost of a CD4 assay which is about $30-$50.

Contact: Gisele Galoustian
ggaloust@fau.edu
561-297-2676
Florida Atlantic University

Public Release: 13-Apr-2016
Nature Communications
Researchers open the way to new treatments for chronic pain and cancer
In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2). Taken in addition to their study of its molecular mechanism last year, Dr. Vera Moiseenkova-Bell's laboratory has revealed TRPV2 as new target for pharmaceutical research treating chronic pain and cancer.

Contact: Marc Kaplan
marc.kaplan@case.edu
216-368-4692
Case Western Reserve University

Public Release: 12-Apr-2016
International Journal of Radiation Oncology • Biology • Physics
Red Journal's May 2016 edition features special focus on particle therapy
The International Journal of Radiation Oncology Biology Physics' (Red Journal) May edition is a special issue focused entirely on particle therapy. It will feature papers showcasing the 'best available evidence' on the value of particle therapy, as well as editorials and commentaries about its place in the radiation therapy (RT) arsenal.

Contact: Erin L. Boyle
erin.boyle@astro.org
703-839-7336
American Society for Radiation Oncology

Public Release: 12-Apr-2016
eLife
Tropical birds develop 'superfast' wing muscles for mating, not flying
Studies in a group of tropical birds have revealed one of the fastest limb muscles on record for any animal with a backbone. The muscle, which can move the wing at more than twice the speeds required for flying, has evolved in association with extravagant courtship displays that involve rapid limb movements, according to a paper to be published in the journal eLife.
Wake Forest University, American Ornithologists' Union

Contact: Emily Packer
e.packer@elifesciences.org
eLife

Public Release: 12-Apr-2016
Proceedings of the National Academy of Sciences
Misregulation of DNA building blocks associated with the development of colon cancer
When cells divide, the proper balance between the four DNA building blocks is required in order for the DNA to be copied without the introduction of potentially harmful mutations. Researchers at Umeå University in Sweden have now shown a connection between levels of DNA building blocks -- dNTPs -- and colon cancer. This discovery has been published in the Proceedings of the National Academy of Sciences.

Contact: Daniel Harju
daniel.harju@umu.se
46-725-522-918
Umea University

Public Release: 12-Apr-2016
Breast Cancer Research
Potential effects of fertility treatments on breast density and cancer risk
Infertility and hormonal fertility treatments may influence the amount of dense tissue in the breast, a risk factor for breast cancer, according to a study involving 43,313 women, published in the open access journal Breast Cancer Research.

Contact: Anne Korn
anne.korn@biomedcentral.com
44-020-319-22744
BioMed Central

Public Release: 12-Apr-2016
Scientific Reports
Mathematics to fight cancer
Mathematicians and physicians at the University of Bonn have developed a new model for immunotherapy of cancer. The method could help to develop new treatment strategies and to understand why some approaches do not work with certain tumors. The study is now appearing in the technical journal 'Scientific Reports'.

Contact: Prof. Dr. Anton Bovier
bovier@uni-bonn.de
49-228-733-413
University of Bonn

Public Release: 12-Apr-2016
International Journal of Radiation Oncology • Biology • Physics
Moffitt researchers discover liver metastases have different radiation sensitivities
Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor.
National Institutes of Health, United States Army Medical Research and Materiel Command, National Functional Genomics Center, Bankhead-Coley Foundation

Contact: Lisa Chillura
lisa.chillura@moffitt.org
813-745-1353
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 12-Apr-2016
Journal of Clinical Oncology
Older women, especially blacks, receive targeted breast cancer treatment at low rates
The advent of targeted drugs for a specific type of breast cancer -- HER2 positive -- has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women.
NIH/National Center for Advancing Translational Sciences, Conquer Cancer Foundation, Susan G. Komen Foundation, UNC Breast Cancer SPORE Grant

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill

Public Release: 11-Apr-2016
Journal of Clinical Oncology
PET scans guiding chemo boosts remission for Hodgkin patients
Using PET imaging to guide chemotherapy treatment significantly increases the number of people who go into remission and also decreases toxic side effects for people with advanced Hodgkin lymphoma, according to research conducted by SWOG and two other National Cancer Institute research groups.
NIH/National Cancer Institute, The David and Patricia Giuliani Family Foundation, Lymphoma Foundation, Adam Spector Fund for Hodgkin Research, and Ernest & Jeanette Dicker Charitable Foundation

Contact: Wendy Lawton
lawtonw@ohsu.edu
503-348-8675
SWOG

Public Release: 11-Apr-2016
Cancer Cell
New public repository of patient-derived cancer models aims to improve drug testing
Testing experimental cancer drugs in mouse models with patient-derived tumors could reduce the high failure rate of drugs in early clinical trials, according to a report from Dana-Farber Cancer Institute scientists.
Leukemia and Lymphoma Society, Stand Up To Cancer

Contact: Teresa Herbert
Teresa_Herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 11-Apr-2016
Annals of Internal Medicine
USPSTF publishes recommendation on taking aspirin to prevent heart attack, stroke, and colorectal cancer
The US Preventive Services Task Force recommends that people who are 50-69 years old, have increased risk of cardiovascular disease (CVD), and who are not at increased risk for bleeding, consider taking aspirin for primary prevention of CVD and colorectal cancer. The full recommendation and evidence reviews are published in Annals of Internal Medicine.

Contact: Cara Graeff
cgraeff@acponline.org
215-351-2513
American College of Physicians

Public Release: 11-Apr-2016
Cancer Cell
Mapping the routes to drug resistance in cancer
When a targeted therapy blocks a pathway that enables tumors to grow, the cells usually manage to get around that obstacle. The result is drug resistance. Researchers have now found a way to map those alternate routes by studying individual cancer cells, suggesting approaches for developing more effective combination therapies. The results are published April 11 in Cancer Cell.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 11-Apr-2016
Cancer
Being married may help prolong survival in cancer patients
New research has uncovered a link between being married and living longer among cancer patients, with the beneficial effect of marriage differing by race/ethnicity and place of birth.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 11-Apr-2016
Cancer
Man and life: How marriage, race and ethnicity and birthplace affect cancer survival
Previous studies have shown that married patients with cancer fare better than unmarried cancer patients, surviving more often and longer. In a new study, published April 11 in the journal Cancer, researchers at University of California, San Diego School of Medicine report that the benefits of being married vary by race and ethnicity, with male non-Hispanic white bachelors experiencing the worst outcome.
Stanford Cancer Institute, NIH/National Cancer Institute, Specialized Cancer Center Support Grant

Contact: Yadira Galindo
ygalindo@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 11-Apr-2016
Cancer Cell
A different route to drug resistance
A team of researchers, led by Ludwig Cancer Research scientist Paul Mischel and James Heath of the California Institute of Technology, has probed biochemical signaling cascades within individual cancer cells to capture a previously poorly understood but clinically significant mechanism of cancer drug resistance.
Ludwig Cancer Research, Ben and Catherine Ivy Foundation Fund, National Institutes of Health, Phelps Family Foundation, National Brain Tumor Society

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research

Public Release: 11-Apr-2016
Journal of Urology
More than 3 percent of men on active surveillance for prostate cancer may have metastases
Active surveillance of prostate cancer is increasingly accepted as an option for treating patients with clinically insignificant disease to maintain their quality of life. Despite close monitoring, however, metastatic disease develops in a small number of men on active surveillance. About 3 percent of patients on surveillance had metastasis by a median of seven years after diagnosis. This risk increased to ten percent in patients with Gleason score (GS) 7, according to new research published in The Journal of Urology.

Contact: Eileen Leahy
jumedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 11-Apr-2016
Journal of Clinical Oncology
Omega factor: Novel method measures mortality risk when multiple diseases threaten
Researchers at the University of California, San Diego School of Medicine have developed a novel method for assessing mortality risk in elderly patients with cancer who also suffer from other serious diseases or conditions. The prognostic model, they say, is more precise and provides a more useful tool for determining the best treatments when more than one disease is involved.
National Institutes of Health

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 11-Apr-2016
Journal of Thoracic Oncology
A novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient
Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors.

Contact: Jeff Wolf
Jeff.Wolf@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 11-Apr-2016
Science
Macrophages surrounding lymph nodes block the progression of melanoma, other cancers
Researchers at Massachusetts General Hospital have identified a type of immune cell that appears to block the progress of melanoma and other cancers in animal models.
Samana Cay MGH Research Scholar Fund, National Institutes of Health

Contact: Julie Cunningham
julie.cunningham@mgh.harvard.edu
617-724-6433
Massachusetts General Hospital

Public Release: 11-Apr-2016
Research Ideas & Outcomes
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer. Taiwanese specialists have now looked into the electronic medical records from a hospital and concluded that the treatment is not as effective in lung cancer cases when compared to any other cancer patients. Their research is published in the open access journal Research Ideas and Outcomes.

Contact: Robert J. Chen
rjcc@ntu.edu.tw
Pensoft Publishers

Showing releases 176-200 out of 1295.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases

     

 

EurekAlert!